Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial - Université de Lorraine Access content directly
Journal Articles European Journal of Heart Failure Year : 2022

Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial

Fichier principal
Vignette du fichier
European J of Heart Fail - 2022 - Butler - Early benefit with empagliflozin in heart failure with preserved ejection.pdf (1.73 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03796827 , version 1 (04-10-2022)

Identifiers

Cite

Javed Butler, Tariq Jamal Siddiqi, Gerasimos Filippatos, João Pedro Ferreira, Stuart J Pocock, et al.. Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial. European Journal of Heart Failure, 2022, 24 (2), pp.245-248. ⟨10.1002/ejhf.2420⟩. ⟨hal-03796827⟩
13 View
176 Download

Altmetric

Share

Gmail Facebook X LinkedIn More